| ALLO |
Allogene Therapeutics, Inc. |
90%
|
Reciprocal relationship from ALLO graph: Reciprocal relationship from CLLS graph: Reciprocal relationship from ALLO graph: the Company acquired certain assets and assumed certain liabilities from Pfi… |
| IOVA |
Iovance Biotherapeutics, Inc. |
85%
|
Reciprocal relationship from IOVA graph: The Company will license gene-editing technology from Cellectis S.A. to develop TIL cell therapies that have been genetically edited, including a PD-1 inactiv… |
| ALLO |
Allogene Therapeutics, Inc. |
72%
|
01 23,658 Gross value at end of period 53,751 18,332 72,083 Accumulated depreciation at end of period ( 31,994 ) ( 16,431 ) ( 48,425 ) Entity-wide disclosures: In 2025, approximately $ 8.3 million o … |
| AUTL |
Autolus Therapeutics plc |
72%
|
ately 14,000 sq. ft. in-house manufacturing facility, which is dedicated to the production of certain critical raw and starting material for clinical supply, with the potential to supply such materia… |
| AUTL |
Autolus Therapeutics plc |
72%
|
Reciprocal relationship from AUTL graph: Reciprocal relationship from CLLS graph: Reciprocal relationship from AUTL graph: Reciprocal relationship from CLLS graph: ately 14,000 sq. ft. in-house manuf… |
| BMY |
Bristol-Myers Squibb Company |
72%
|
ately 14,000 sq. ft. in-house manufacturing facility, which is dedicated to the production of certain critical raw and starting material for clinical supply, with the potential to supply such materia… |
| BMY |
Bristol-Myers Squibb Company |
72%
|
Reciprocal relationship from BMY graph: Reciprocal relationship from CLLS graph: Reciprocal relationship from BMY graph: Reciprocal relationship from CLLS graph: Reciprocal relationship from BMY grap… |
| BMYMP |
Bristol-Myers Squibb Co |
72%
|
ately 14,000 sq. ft. in-house manufacturing facility, which is dedicated to the production of certain critical raw and starting material for clinical supply, with the potential to supply such materia… |
| BMYMP |
Bristol-Myers Squibb Co |
72%
|
Reciprocal relationship from BMYMP graph: Reciprocal relationship from CLLS graph: Reciprocal relationship from BMYMP graph: Reciprocal relationship from CLLS graph: Reciprocal relationship from BMYM… |
| DTIL |
Precision BioSciences, Inc. |
72%
|
ately 14,000 sq. ft. in-house manufacturing facility, which is dedicated to the production of certain critical raw and starting material for clinical supply, with the potential to supply such materia… |
| DTIL |
Precision BioSciences, Inc. |
72%
|
Reciprocal relationship from DTIL graph: Reciprocal relationship from CLLS graph: Reciprocal relationship from DTIL graph: Reciprocal relationship from CLLS graph: Reciprocal relationship from DTIL g… |
| IOVA |
Iovance Biotherapeutics, Inc. |
72%
|
han we anticipate or may result in delays. In addition, if supply from one approved manufacturer or supplier, including our own in-house manufacturing facilities, is interrupted, there could be a sig… |
| LYEL |
Lyell Immunopharma, Inc. |
72%
|
Reciprocal relationship from LYEL graph: Reciprocal relationship from CLLS graph: ately 14,000 sq. ft. in-house manufacturing facility, which is dedicated to the production of certain critical raw an… |
| LYEL |
Lyell Immunopharma, Inc. |
72%
|
ately 14,000 sq. ft. in-house manufacturing facility, which is dedicated to the production of certain critical raw and starting material for clinical supply, with the potential to supply such materia… |
| NTLA |
Intellia Therapeutics, Inc. |
72%
|
Reciprocal relationship from NTLA graph: Reciprocal relationship from CLLS graph: ately 14,000 sq. ft. in-house manufacturing facility, which is dedicated to the production of certain critical raw an… |
| NTLA |
Intellia Therapeutics, Inc. |
72%
|
ately 14,000 sq. ft. in-house manufacturing facility, which is dedicated to the production of certain critical raw and starting material for clinical supply, with the potential to supply such materia… |
| PGEN |
Precigen, Inc. |
72%
|
Reciprocal relationship from PGEN graph: Reciprocal relationship from CLLS graph: Reciprocal relationship from PGEN graph: Reciprocal relationship from CLLS graph: Reciprocal relationship from PGEN g… |
| TKPHF |
Takeda Pharmaceutical Company Limited |
72%
|
ately 14,000 sq. ft. in-house manufacturing facility, which is dedicated to the production of certain critical raw and starting material for clinical supply, with the potential to supply such materia… |
| TKPHF |
Takeda Pharmaceutical Company Limited |
72%
|
Reciprocal relationship from TKPHF graph: Reciprocal relationship from CLLS graph: ately 14,000 sq. ft. in-house manufacturing facility, which is dedicated to the production of certain critical raw a… |
| TMO |
Thermo Fisher Scientific Inc. |
72%
|
ately 14,000 sq. ft. in-house manufacturing facility, which is dedicated to the production of certain critical raw and starting material for clinical supply, with the potential to supply such materia… |
| TMO |
Thermo Fisher Scientific Inc. |
72%
|
Reciprocal relationship from TMO graph: Reciprocal relationship from CLLS graph: ately 14,000 sq. ft. in-house manufacturing facility, which is dedicated to the production of certain critical raw and… |
| ASTRAZENECA-HOLDINGS |
ASTRAZENECA-HOLDINGS |
62%
|
land Limited, and AstraZeneca Holdings B.V., alleging that Cellectis' TALEN-based gene editing technology would infringe three of Factor's U.S. patents. Due to the early stage of this claim, our beli… |
| ASTRAZENECA-IRELAND-LIMITED |
ASTRAZENECA-IRELAND-LIMITED |
62%
|
en members of the Group are eliminated in full consolidation. If the Group loses control of a subsidiary, the subsidiary is deconsolidated as of the date control is lost. At the date when control is … |
| AZ-HOLDINGS |
AZ-HOLDINGS |
62%
|
Preferred Shares and 18,000,000 Class B Preferred Shares, in each case at a price of $ 5.00 per share. Both classes of preferred shares benefit from a liquidation preference and are convertible into … |
| AZN |
AstraZeneca PLC |
62%
|
Reciprocal relationship from AZN graph: Reciprocal relationship from CLLS graph: en members of the Group are eliminated in full consolidation. If the Group loses control of a subsidiary, the subsidia… |
| CELLECTIS-S-A-CELLECTIS-INC |
CELLECTIS-S-A-CELLECTIS-INC |
62%
|
in 2024 to $ 35.1 million in 2025). Selling, general and administrative expenses increased by $ 0.7 million between the years ended December 31, 2024 and 2025 mainly due to a $ 0.6 million increase i… |
| CIBUS-GLOBAL-LLC |
CIBUS-GLOBAL-LLC |
62%
|
han we anticipate or may result in delays. In addition, if supply from one approved manufacturer or supplier, including our own in-house manufacturing facilities, is interrupted, there could be a sig… |
| COMPANY-TWO-AZ-HOLDINGS |
COMPANY-TWO-AZ-HOLDINGS |
62%
|
of resources or reduced manufacturing yields, any of which would negatively impact our operating results. Further, we may be unable to enter into agreements with a new supplier on commercially reason… |
| FACTOR-BIOSCIENCES-INC |
FACTOR-BIOSCIENCES-INC |
62%
|
han we anticipate or may result in delays. In addition, if supply from one approved manufacturer or supplier, including our own in-house manufacturing facilities, is interrupted, there could be a sig… |
| FRENCH-REPUBLIC-GROUP |
FRENCH-REPUBLIC-GROUP |
62%
|
of the federal False Claims Act (discussed below). The civil monetary penalties statute imposes penalties against any person or entity who, among other things, is determined to have presented or caus… |
